Recursion Initiates FDA Talks for REC-4881 Registrational Study, Reports Positive Clinical Data
RXRX sits 20% above its 52-week low of $2.8.
Summary
Recursion Pharmaceuticals reported its first-quarter financial results and provided a significant business update, highlighting strong clinical pipeline execution. The company announced favorable preliminary safety and pharmacokinetic data for REC-1245 in its Phase 1/2 DAHLIA study, showing it was well-tolerated with no dose-limiting toxicities observed to date. Most notably, Recursion has initiated engagement with the FDA to align on a potential registrational study design for REC-4881, an allosteric MEK1/2 inhibitor for familial adenomatous polyposis, with an update expected in the second half of 2026. Additionally, the first patient has been dosed in the ENLYGHT Phase 1 clinical study for REC-4539, an AI-designed LSD1 inhibitor. This news, released just prior to the official 8-K and 10-Q filings, signals significant progress in de-risking its lead clinical assets and advancing its pipeline towards potential commercialization, which is highly material for a clinical-stage biotech. Investors will be closely watching for further updates on the FDA alignment for REC-4881 and continued clinical trial data.
At the time of this announcement, RXRX was trading at $3.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $2.80 to $7.18. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.